Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

REGEN-COV lowers risk of symptomatic COVID-19 infections by 81% in study

FDA recently authorized that the use of the monoclonal antibody cocktail as a post-exposure prophylaxis in some individuals.

By Brian Buntz | August 4, 2021

RegeneronRegeneron’s (NSDQ:REGN) REGEN-COV remains one of the most effective monoclonal antibody therapies in reducing the risk of serious COVID-19 infections and resulting hospitalizations and deaths. A study recently published in the New England Journal of Medicine found that the drug effectively prevented COVID-19 disease in household contacts of individuals infected with the novel coronavirus.

When delivered subcutaneously, REGEN-COV was 81.4% effective at reducing the risk of symptomatic infections and led to a 92.6% reduction of symptomatic infections after the first week.

Consisting of the monoclonal antibodies casirivimab and imdevimab, REGEN-COV also appeared to accelerate the recovery of COVID-19-infected individuals. In recipients who received the drug, symptoms resolved two weeks faster than in placebo recipients.

REGEN COVStudy investigators also found that the drug was generally well-tolerated.

“This peer-reviewed NEJM publication demonstrates that REGEN-COV provides rapid and robust protection to prevent SARS-CoV-2 infection, and follows data showing that REGEN-COV maintains effectiveness against all variants of concern,” said Dr. George D. Yancopoulos, president and CSO at Regeneron, in a statement.

The study involved 1505 participants 12 or older. Among the 753 participants in the REGEN-COV group, 11 (1.5%) developed symptomatic COVID-19 compared. Conversely, 59 out of 752 placebo recipients (7.8%) developed symptomatic disease. The relative risk reduction was 81.4%.

 


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: coronavirus, covid-19, FDA, monoclonal antibody, REGEN-COV, Regeneron, SARS-CoV-2
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Janssen
Janssen’s company group chairman dishes on growth strategy
Curebase
Curebase raises $40 million in Series B funding round 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50